Bookmark


  • Page views 501
  • PDF Downloads 58


ISSN: 2766-2276
Medicine Group . 2022 May 18;3(5):552-555. doi: 10.37871/jbres1478.

 |   |   | 


open access journal Mini Review

Review: The Commonality of Energy Metabolism of Starvation, Disorders of Glucose-Lipid Metabolism, Diabetes Mellitus and Cachexia

Shaoqing Lai*

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China
*Corresponding author: Shaoqing Lai, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China E-mail:
Received: 05 May 2022 | Accepted: 17 May 2022 | Published: 18 May 2022
How to cite this article: Lai S. Review: The Commonality of Energy Metabolism of Starvation, Disorders of Glucose-Lipid Metabolism, Diabetes Mellitus and Cachexia. J Biomed Res Environ Sci. 2022 May 18; 3(5): 552-555. doi: 10.37871/jbres1478, Article ID: jbres1478
Copyright:© 2022 Lai S. Distributed under Creative Commons CC-BY 4.0.
Keywords
  • Starvation
  • Diabetes mellitus
  • Cachexia
  • Energy metabolism
  • Insulin resistance
  • Stress response

Diabetes mellitus, pathoglycemia, dyslipidemia, non-alcoholic fatty liver, overweight, hypertension, and atherosclerosis are common diseases endangering human health. Cachexia is a life-threatening disease condition. Cachexia is associated with increased mortality. Cancer patients with cachexia are less tolerant and have a decreased response to chemotherapy and radiation. Do these diseases have a common pathogenesis? We will discuss the commonality of energy metabolism in starvation, disorders of glucose-lipid metabolism, diabetes mellitus and cachexia, and how the stress response alters the pattern of energy metabolism.

Diabetes mellitus, pathoglycemia, dyslipidemia, non-alcoholic fatty liver, overweight, hypertension, and atherosclerosis are common diseases endangering human health. There were 424 million people worldwide suffered from diabetes mellitus in 2020, and the number is expected to increase to 552 million by 2030 [1]. Cachexia is a state of poor nutrition associated with increased mortality [2], weight loss and decreased skeletal muscle mass are characteristic symptoms of cachexia. Cachexia affects the majority of cancer patients [3,4], but cachexia is not unique to cancer patients. Cachexia also occurs in late stage of many benign diseases, such as chronic heart failure, chronic renal failure, and autoimmune diseases. Cancer patients with cachexia are less tolerant and have a decreased response to chemotherapy and radiation [5]. Cancer cachexia encompasses distinct stages of pre-cachexia, cachexia, and refractory cachexia been validated in the clinical setting [6,7], and cachexia cannot be reversed by nutritional support. In this review, we will discuss the common biological metabolic mechanism in starvation, disorders of glucose-lipid metabolism, diabetes mellitus and cachexia, and explore potential therapeutic options for disorders of glucose-lipid metabolism, diabetes mellitus and cachexia.

The commonality of energy metabolism of starvation, disorders of glucose-lipid metabolism, diabetes mellitus and cachexia

Energy metabolism in starvation state: In starvation state, firstly hepatic glycogen is converted into glucose to replenish blood sugar, then amino acids are converted into glucose in liver, and fat is decomposed into fatty acid and ketone body. When fat is exhausted, the energy supply depends on decomposition of protein [8-11]. When the protein exhausted more than 40% of total body, the life is threatened.

The brain is a vital organ of the body. Brain cells rely on glucose or ketone body for energy. The metabolism in brain is very active, 20-25% of total oxygen and 20% of total glucose is consumed in brain, even in starvation state, the brain needs an adequate supply of energy. The red blood cells only depend on the energy from glycolysis.

The biological energy materials include carbohydrate, fat, and protein. When food is abundant, insulin promotes cells to convert glucose into glycogen reserved in the liver and muscles, fatty acid into triglyceride stored in fat cells, and amino acids into protein reserved in muscles. When there are no food available, hyperglycemic hormones promote cells to convert hepatic glycogen into glucose to replenish blood sugar, and initiate gluconeogenesis to convert amino acids into glucose in liver, and initiate lipid mobilization to decompose fat into fatty acid and ketone body. Insulin is the only hormone to promote organismic cells to store energy. On the contrary, there are many hyperglycemic hormones to promote organism to use the energy stored in cells.

1.1.1. Prolonged starvation triggers stress response to alter pattern of energy metabolism. Stress response is non-specific reaction of organism to various stressors. Stress response coordinates functions of systems to overcome risk status. The core of stress response is the axis of hypothalamus, pituitarium and adrenal cortex. Stress response is characterized by a large amount of adrenal cortical hormone. Adrenal corticosteroids resist the function of insulin, and work with hyperglycemic hormones to initiate gluconeogenesis and lipid mobilization. Adrenal corticosteroid alters the pattern of energy metabolism that prevents tissues except brain from consuming glucose, and ensures the adequate supply of glucose for the brain and adequate fatty acid supply for other tissues in starvation state. Without external energy supplement, the quantity of fat determines the survival time of starvation.

Energy metabolism in disorders of glucose-lipid metabolism, diabetes mellitus and cachexiaManifestation: Hyperglycemia, essential hypertension and coronary heart disease are the main manifestations of disorders of glucose-lipid metabolism. Insulin resistance is the common pathological basis of essential hypertension, coronary heart disease and hyperlipidemia [12-15]. The inhibitory effect of insulin on lipolysis is weakened by insulin resistance, free fatty acids are released into circulation [16]. The free fatty acids stimulate liver cells to synthesize and release triglycerides leading to low-density lipoprotein increase and high-density lipoprotein decrease, and the formation of hypertriglyceridemia [17]. The effect of insulin stimulating hemangiectasis through nitric oxide release is weakened by insulin resistance [18,19], and on the contrary, the effect of insulin promoting reabsorption of sodium salts and stimulating proliferation of vascular smooth muscle cell and angiotensin producing is significantly enhanced by insulin resistance [20] leading to high blood pressure.

Hyperglycemia and lipid mobilization are main manifestations of diabetes mellitus. Insulin resistance plays an important role in diabetes mellitus [21,22]. As insulin resistance outlasts compensatory ability of pancreatic beta cells, glucose intolerance and hyperglycemia occur [23].

Weight loss, especially with decreasing skeletal muscle mass, is manifestation of cachexia [24,25]. The 2008 consensus of cachexia emphasized that cachexia is an energy metabolic syndrome affecting glucose, lipid, protein [26]. Insulin resistance plays an important role in cancer cachexia [21,22]. The skeletal muscle is a highly plastic tissue with the ability to adapt its structure and metabolism in response to different physiological stimuli. Only when fat is exhausted, the energy supply depends on decomposition of protein. When the protein exhausted more than 40% of total body, the life is threatened. Adipose tissue has white and brown adipose tissue. White adipose tissue and brown adipose tissue are different in distribution, morphology and function. White adipose tissue mainly serves as energy storage organ; brown adipose tissue is used for thermogenesis in colder conditions, inflammation and other critical state. Brown adipose tissue found in cachectic mice and patients [27,28] indicates the body in a serious critical condition.Causes: Insulin resistance, as a physiological adaptive response, is a significant feature in the setting of fasting, exercise, acute stress, and pregnancy [29]. Insulin resistance ensures vital organs the brain an adequate glucose supply in a crisis situation. The physiological mechanism behind insulin resistance is the stress response. The stress response alters energy metabolism patterns through insulin resistance.

Stress response is non-specific reaction to various stressors, many stressors, such as starvation, inflammation and physical or psychic trauma, can induce stress response. The chronic systemic inflammatory response is one of important causes of stress response in disorders of glucose-lipid metabolism, diabetes mellitus and cachexia. Chronic inflammatory responses lead to insulin resistance, various metabolic abnormalities and glucolipid metabolic diseases [30-32]. Immunological and neuroendocrinological abnormalities play an important role in Cachexia [33,34]. Insulin resistance in cancer cachexia has been attributed to chronic exposure of pro-inflammatory cytokines including Tumor Necrosis Factor (TNF)-a, Interleukin (IL)-6, and Insulin-Like Growth Factor (IGF) binding protein [35]. The level of growth hormone, epinephrine, glucagon, and adrenocorticotropic hormone and corticotropin releasing factors is high in patients with cancer cachexia [36]. These studies observed a relationship between inflammatory response and insulin resistance, but ignored the intermediate link between them, the stress response (Table 1).

Table 1: Process of energy expenditure caused by insulin resistance.
  Glycogen conversion gluconeogenesis lipid mobilization Protein decomposition
Short-Term Starvation    
Long-Term Starvation    
Disorders of Glucose-Lipid Metabolism      
Diabetes Mellitus      
Cachexia      

Stress response coordinates functions of systems organism to overcome risk state. Stress response is non-specific reaction, many factors, such as inflammation, physical or psychic trauma can induce stress response. Stress hormones alter the pattern of energy metabolism by insulin resistance to ensure the brain adequate glucose supply in risk condition.

Although the causes are different, there is commonality of energy metabolism in starvation, disorders of glucose-lipid metabolism, diabetes mellitus and cachexia. Disorders of glucose-lipid metabolism and diabetes mellitus are characterizing by overconsumption of lipid. Cachexia is characterizing by overconsumption of protein. Disorders of glucose-lipid metabolism, diabetes mellitus and cachexia are manifestations in different stages of the altered energy metabolism. To return the altered energy metabolism to normal energy metabolic process, it is necessary to eliminate the stressors and to calm the stress responses. The treatment directed at underlying endocrine dysfunctions may lead to potential therapeutic options for disorders of glucose-lipid metabolism, diabetes mellitus and cachexia.

  1. BELL ET. Carcinoma of the pancreas. I. A clinical and pathologic study of 609 necropsied cases. II. The relation of carcinoma of the pancreas to diabetes mellitus. Am J Pathol. 1957 May-Jun;33(3):499-523. PMID: 13424657; PMCID: PMC1934687.
  2. Bennani-Baiti N, Walsh D. What is cancer anorexia-cachexia syndrome? A historical perspective. J R Coll Physicians Edinb. 2009 Sep;39(3):257-62. PMID: 20608345.
  3. Roeland EJ, Bohlke K, Baracos VE, Bruera E, Del Fabbro E, Dixon S, Fallon M, Herrstedt J, Lau H, Platek M, Rugo HS, Schnipper HH, Smith TJ, Tan W, Loprinzi CL. Management of Cancer Cachexia: ASCO Guideline. J Clin Oncol. 2020 Jul 20;38(21):2438-2453. doi: 10.1200/JCO.20.00611. Epub 2020 May 20. PMID: 32432946.
  4. Farkas J, von Haehling S, Kalantar-Zadeh K, Morley JE, Anker SD, Lainscak M. Cachexia as a major public health problem: frequent, costly, and deadly. J Cachexia Sarcopenia Muscle. 2013 Sep;4(3):173-8. doi: 10.1007/s13539-013-0105-y. Epub 2013 Mar 29. PMID: 23539127; PMCID: PMC3774921.
  5. Fearon KC, Baracos VE. Cachexia in pancreatic cancer: new treatment options and measures of success. HPB (Oxford). 2010 Jun;12(5):323-4. doi: 10.1111/j.1477-2574.2010.00178.x. PMID: 20590907; PMCID: PMC2951820.
  6. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011 May;12(5):489-95. doi: 10.1016/S1470-2045(10)70218-7. Epub 2011 Feb 4. PMID: 21296615.
  7. Vigano AAL, Morais JA, Ciutto L, Rosenthall L, di Tomasso J, Khan S, Olders H, Borod M, Kilgour RD. Use of routinely available clinical, nutritional, and functional criteria to classify cachexia in advanced cancer patients. Clin Nutr. 2017 Oct;36(5):1378-1390. doi: 10.1016/j.clnu.2016.09.008. Epub 2016 Sep 20. PMID: 27793524.
  8. Waterlow JC, Prorein-energy malnutrition [M]. 2nd ed London Edward Arnold. 1992:96-97.
  9. Young VR, Marchini JS, Cortiella J. Assessment of protein nutritional status. J Nutr. 1990 Nov;120 Suppl 11:1496-502. doi: 10.1093/jn/120.suppl_11.1496. PMID: 2243295.
  10. Abumrad NN, Yazigi N, Cersosimo E, Hourani H, Gedde S, Bulus N, Williams P. Glutamine metabolism during starvation. JPEN J Parenter Enteral Nutr. 1990 Jul-Aug;14(4 Suppl):71S-76S. doi: 10.1177/014860719001400408. PMID: 2402056.
  11. Espat JN, Copeland EM, Souba WW, Influence of fasting on glutamine transport in rat liver [J] JPEN. 1993;17(6):493-500. https://bit.ly/3MoMi5Q
  12. Ye DW, Rong XL, Xu AM, Guo J. Liver-adipose tissue crosstalk: A key player in the pathogenesis of glucolipid metabolic disease. Chin J Integr Med. 2017 Jun;23(6):410-414. doi: 10.1007/s11655-017-2810-4. Epub 2017 Aug 10. PMID: 28795382.
  13. Barton JC, Barton JC, Adams PC, Acton RT. Risk Factors for Insulin Resistance, Metabolic Syndrome, and Diabetes in 248 HFE C282Y Homozygotes Identified by Population Screening in the HEIRS Study. Metab Syndr Relat Disord. 2016 Mar;14(2):94-101. doi: 10.1089/met.2015.0123. Epub 2016 Jan 15. PMID: 26771691; PMCID: PMC4955606.
  14. Tan C, Sasagawa Y, Mori M. The association between insulin resistance, metabolic syndrome, and ischemic heart disease among Rumoi residents. J Gen Fam Med. 2017 Jun 15;18(6):360-364. doi: 10.1002/jgf2.94. PMID: 29264065; PMCID: PMC5729322.
  15. Brown AE, Walker M. Genetics of Insulin Resistance and the Metabolic Syndrome. Curr Cardiol Rep. 2016 Aug;18(8):75. doi: 10.1007/s11886-016-0755-4. PMID: 27312935; PMCID: PMC4911377.
  16. Zhang N, Zhang N, Song L, Xie H, Zhao C, Li S, Zhao W, Zhao Y, Gao C, Xu G. Adipokines and free fatty acids regulate insulin sensitivity by increasing microRNA-21 expression in human mature adipocytes. Mol Med Rep. 2017 Aug;16(2):2254-2258. doi: 10.3892/mmr.2017.6769. Epub 2017 Jun 14. PMID: 28627656.
  17. Li YX, Han TT, Liu Y, Zheng S, Zhang Y, Liu W, Hu YM. Insulin resistance caused by lipotoxicity is related to oxidative stress and endoplasmic reticulum stress in LPL gene knockout heterozygous mice. Atherosclerosis. 2015 Mar;239(1):276-82. doi: 10.1016/j.atherosclerosis.2015.01.020. Epub 2015 Jan 23. PMID: 25635326.
  18. Laakso M, Edelman SV, Brechtel G, Baron AD. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance. J Clin Invest. 1990 Jun;85(6):1844-52. doi: 10.1172/JCI114644. PMID: 2189893; PMCID: PMC296649.
  19. Laakso M, Edelman SV, Brechtel G, Baron AD. Impaired insulin-mediated skeletal muscle blood flow in patients with NIDDM. Diabetes. 1992 Sep;41(9):1076-83. doi: 10.2337/diab.41.9.1076. PMID: 1499861.
  20. Strazzullo P, Barbato A, Galletti F, Barba G, Siani A, Iacone R, D'Elia L, Russo O, Versiero M, Farinaro E, Cappuccio FP. Abnormalities of renal sodium handling in the metabolic syndrome. Results of the Olivetti Heart Study. J Hypertens. 2006 Aug;24(8):1633-9. doi: 10.1097/01.hjh.0000239300.48130.07. PMID: 16877967.
  21. Tuck ML, Bounoua F, Eslami P, Nyby MD, Eggena P, Corry DB. Insulin stimulates endogenous angiotensin II production via a mitogen-activated protein kinase pathway in vascular smooth muscle cells. J Hypertens. 2004 Sep;22(9):1779-85. doi: 10.1097/00004872-200409000-00023. PMID: 15311107.
  22. Odegaard JI, Chawla A. Pleiotropic actions of insulin resistance and inflammation in metabolic homeostasis. Science. 2013 Jan 11;339(6116):172-7. doi: 10.1126/science.1230721. PMID: 23307735; PMCID: PMC3725457.
  23. Geijselaers SLC, Sep SJS, Claessens D, Schram MT, van Boxtel MPJ, Henry RMA, Verhey FRJ, Kroon AA, Dagnelie PC, Schalkwijk CG, van der Kallen CJH, Biessels GJ, Stehouwer CDA. The Role of Hyperglycemia, Insulin Resistance, and Blood Pressure in Diabetes-Associated Differences in Cognitive Performance-The Maastricht Study. Diabetes Care. 2017 Nov;40(11):1537-1547. doi: 10.2337/dc17-0330. Epub 2017 Aug 25. PMID: 28842522.
  24. Argilés JM, Busquets S, Stemmler B, López-Soriano FJ. Cancer cachexia: understanding the molecular basis. Nat Rev Cancer. 2014 Nov;14(11):754-62. doi: 10.1038/nrc3829. Epub 2014 Oct 9. PMID: 25291291.
  25. Zagzag J, Hu MI, Fisher SB, Perrier ND. Hypercalcemia and cancer: Differential diagnosis and treatment. CA Cancer J Clin. 2018 Sep;68(5):377-386. doi: 10.3322/caac.21489. Epub 2018 Sep 21. PMID: 30240520.
  26. Evans WJ, Morley JE, Argilés J, Bales C, Baracos V, Guttridge D, Jatoi A, Kalantar-Zadeh K, Lochs H, Mantovani G, Marks D, Mitch WE, Muscaritoli M, Najand A, Ponikowski P, Rossi Fanelli F, Schambelan M, Schols A, Schuster M, Thomas D, Wolfe R, Anker SD. Cachexia: a new definition. Clin Nutr. 2008 Dec;27(6):793-9. doi: 10.1016/j.clnu.2008.06.013. Epub 2008 Aug 21. PMID: 18718696.
  27. Brooks SL, Neville AM, Rothwell NJ, Stock MJ, Wilson S. Sympathetic activation of brown-adipose-tissue thermogenesis in cachexia. Biosci Rep. 1981 Jun;1(6):509-17. doi: 10.1007/BF01121584. PMID: 7295902.
  28. Shellock FG, Riedinger MS, Fishbein MC. Brown adipose tissue in cancer patients: possible cause of cancer-induced cachexia. J Cancer Res Clin Oncol. 1986;111(1):82-5. doi: 10.1007/BF00402783. PMID: 3949854.
  29. Soeters MR, Soeters PB. The evolutionary benefit of insulin resistance. Clin Nutr. 2012 Dec;31(6):1002-7. doi: 10.1016/j.clnu.2012.05.011. Epub 2012 Jun 7. PMID: 22682085.
  30. Welty FK, Alfaddagh A, Elajami TK. Targeting inflammation in metabolic syndrome. Transl Res. 2016 Jan;167(1):257-80. doi: 10.1016/j.trsl.2015.06.017. Epub 2015 Jul 3. PMID: 26207884; PMCID: PMC6800061.
  31. Cooke AA, Connaughton RM, Lyons CL, McMorrow AM, Roche HM. Fatty acids and chronic low grade inflammation associated with obesity and the metabolic syndrome. Eur J Pharmacol. 2016 Aug 15;785:207-214. doi: 10.1016/j.ejphar.2016.04.021. Epub 2016 Apr 12. PMID: 27083551.
  32. Domingueti CP, Dusse LM, Carvalho Md, de Sousa LP, Gomes KB, Fernandes AP. Diabetes mellitus: The linkage between oxidative stress, inflammation, hypercoagulability and vascular complications. J Diabetes Complications. 2016 May-Jun;30(4):738-45. doi: 10.1016/j.jdiacomp.2015.12.018. Epub 2015 Dec 18. PMID: 26781070.
  33. Fearon KC, Glass DJ, Guttridge DC. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. 2012 Aug 8;16(2):153-66. doi: 10.1016/j.cmet.2012.06.011. Epub 2012 Jul 12. PMID: 22795476.
  34. Petruzzelli M, Wagner EF. Mechanisms of metabolic dysfunction in cancer-associated cachexia. Genes Dev. 2016 Mar 1;30(5):489-501. doi: 10.1101/gad.276733.115. PMID: 26944676; PMCID: PMC4782044.
  35. Wang H, Ye J. Regulation of energy balance by inflammation: common theme in physiology and pathology. Rev Endocr Metab Disord. 2015 Mar;16(1):47-54. doi: 10.1007/s11154-014-9306-8. PMID: 25526866; PMCID: PMC4346537.
  36. Tsirona S, Tzanela M, Botoula E, Belenis I, Rondogianni D, Tsagarakis S. CLINICAL PRESENTATION AND LONG-TERM OUTCOME OF PATIENTS WITH ECTOPIC ACTH SYNDROME DUE TO BRONCHIAL CARCINOID TUMORS: A ONE-CENTER EXPERIENCE. Endocr Pract. 2015 Oct;21(10):1104-10. doi: 10.4158/EP15647.OR. Epub 2015 Jun 29. PMID: 26121441.

Content Alerts

SignUp to our
Content alerts.


Creative Commons License This work is licensed under a Creative Commons Attribution 4.0 International License.